BioLargo, Inc. (OTC:BLGO) Q3 2022 Earnings Call Transcript

Page 8 of 8

And so what you do is you say, I want to put less dollars in R&D, but I want to deploy people in the most excellent way because they’re so valuable and that’s what we’re doing across the board. So, no, I don’t think they’re going to go down. I don’t think they’re going to go down. I think flat and even increase as we increase the revenue profile is probably more likely. I also think, too, that infrastructure-wise, we want to grow the infrastructure to be fully qualified for a national exchange and the demands as a very large public company, not a small public company that’s up in company. That’s going to take some manpower. Our historical strategies has to change is to do that as we are stretched because of the expansion in the revenue and all the demands that come to the company, not before.

So, while we may see SG&A increase, we’re also going to see a corresponding increase in revenues to pay that bill. I mean I’d love to say let’s get this thing to profitability and sit back and saw going to be rosy. The reality is we’re going to grow if you’re going to do what we’re talking about doing, you’re going to need more staff, that’s just all there’s to it. You can’t — we’re working triple time over here. And I will say that everybody loves it. The culture is so attractive to people that have spent a career working in a place where maybe they don’t feel the direct impact — direct impact for good for their work. Their tolerance of taking extra risk to do something that no one’s ever done before. It creates a place where people want to be.

And for good reason. I mean, we — as we say, we’re looking for the cutting edge and we live there, right? And then we — and we got more technology coming. So, anyway — I think flat at best. I think increasing with revenue is more likely. And we’ll keep a keen eye on cash flow. How’s that? That’s the way we think. Okay?

Brian Loper: Excellent. All right. Well, thank you very much, Dennis. Very informative. A lot of good things going on, so.

Dennis Calvert: Yes. Let me close with two things real quick.

Brian Loper: Any more — any more comments?

Dennis Calvert: I have two comments real quick. Two; one is, if you haven’t bought POOPH, shame on you. Go out there and buy one and try it. Give it to a friend if you don’t have a pet, you use it for something else. I mean, it’s incredible, right? You’re not going to hurt us sold, it really works. And the second is to be sure and tell your friends about the company to do a deep dive. This is a great company, and we’re proud of it, and you can be proud of it, too, and we think the future is bright. So dig in deep, the more you dig, the more you like it. And we’re going to keep plugging away, all right? Thank you very much, everybody.

Brian Loper: Thank you, Dennis.

Operator: Ladies and gentlemen, this does conclude today’s conference call. You may disconnect your phone lines at this time. Have a wonderful evening. Thank you for your participation.

Brian Loper: Thank you. Thank you.

Follow Biolargo Inc. (OTCMKTS:BLGO)

Page 8 of 8